Abstract
The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G), resulting in the induction of p53-responsive genes (p21WAF1,MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21WAF1 and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53.
Similar content being viewed by others
References
Abarzua P, LoSardo JE, Gubler ML and Neri A . (1995). Cancer Res., 55, 3490–3494.
Abarzua P, LoSardo JE, Gubler ML, Spathis R, Lu YA, Felix A and Neri A . (1996). Oncogene, 13, 2477–2482.
Barak Y, Juven T, Haffner R and Oren M . (1993). EMBO J., 12, 461–468.
Bargonetti J, Manfredi JJ, Chen X, Marshak DR and Prives C . (1993). Genes Dev., 7, 2565–2574.
Boyd KE, Wells J, Gutman J, Bartley SM and Farnham PJ . (1998). Proc. Natl. Acad. Sci. USA, 95, 13887–13892.
Brachmann RK, Yu K, Eby Y, Pavletich NP and Boeke JD . (1998). EMBO J., 17, 1847–1859.
Brown CR, Hong-Brown LQ and Welch WJ . (1997). J Clin. Invest., 99, 1432–1444.
Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G and Lichtiger B . (1990). Oncology, 47, 101–114.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G . (2002). Nat. Med., 8, 282–288.
Cho Y, Gorina S, Jeffrey PD and Pavletich NP . (1994). Science, 265, 346–355.
Foster BA, Coffey HA, Morin MJ and Rastinejad F . (1999). Science, 286, 2507–2510.
Freedman DA, Epstein CB, Roth JC and Levine AJ . (1997). Mol. Med., 3, 248–259.
Froelich-Ammon SJ, Patchan MW, Osheroff N and Thompson RB . (1995). J. Biol. Chem., 270, 14998–15004.
Gannon JV, Greaves R, Iggo R and Lane DP . (1990). EMBO J., 9, 1595–1602.
Gouyette A, Huertas D, Droz JP, Rouesse J and Amiel JL . (1982). Eur. J. Cancer Clin. Oncol., 18, 1285–1292.
Haupt Y, Maya R, Kazaz A and Oren M . (1997). Nature, 387, 296–299.
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC . (1994). Nucleic Acids Res., 22, 3551–3555.
Honda R, Tanaka and Yasuda H . (1997). FEBS Lett., 420, 25–27.
Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP and Azab M . (1994). Am. J. Clin. Oncol., 17, 242–245.
Kubbutat MHG, Jones SN and Vousden KH . (1997). Nature, 387, 299–303.
Midgley CA and Lane DP . (1997). Oncogene, 15, 1179–1189.
Ohnishi T, Ohnishi K, Wang X, Takahashi A and Okaichi K . (1999). Radiat. Res., 151, 498–500.
Peng Y, Chen L, Li C, Lu W and Chen J . (2001). J. Biol. Chem., 276, 40583–40590.
Pochampally R, Fodera B, Chen L, Lu W and Chen J . (1999). J. Biol. Chem., 274, 15271–15277.
Pochampally R, Li C, Lu W, Chen L, Luftig R, Lin J and Chen J . (2000). Biochem. Biophys. Res. Commun., 279, 1001–1010.
Rouesse J, Spielmann M, Turpin F, Le Chevalier T, Azab M and Mondesir JM . (1993). Eur. J. Cancer, 29A, 856–859.
Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC and Wiman KG . (1997). Nat. Med., 3, 632–638.
Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH and Weinstein JN . (1998). Mol. Pharmacol., 53, 241–251.
Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK and Iacopetta BJ . (1996). Hum. Pathol., 27, 1050–1055.
Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N and Ohashi M . (1999). Anticancer. Res., 19, 3099–3108.
Sugikawa E, Tsunoda S, Nakanishi N and Ohashi M . (2002). Anticancer Res., 21, 2671–2675.
Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA and Lane DP . (1995). Oncogene., 10, 389–393.
Wieczorek AM, Waterman JL, Waterman MJ and Halazonetis TD . (1996). Nat. Med., 2, 1143–1146.
Wu X, Bayle JH, Olson D and Levine AJ . (1993). Genes Dev., 7, 1126–1132.
Zhang W, Guo XY, Hu GY, Liu WB, Shay JW and Deisseroth AB . (1994). EMBO J., 13, 2535–2544.
Acknowledgements
We thank Dr Farzan Rastinejad for the CP31398 compound, Dr Hua Lu for providing purified p53, and the Molecular Biology Core of Moffitt Cancer Center for real-time PCR analysis. We are also grateful to Dr Robert Schultz for providing ellipticine and its derivatives. This work was supported by grants from the American Cancer Society and National Institutes of Health to J Chen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peng, Y., Li, C., Chen, L. et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22, 4478–4487 (2003). https://doi.org/10.1038/sj.onc.1206777
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206777
- Springer Nature Limited
Keywords
This article is cited by
-
Recent aspects of the effects of zinc on human health
Archives of Toxicology (2020)
-
Effect of new olivacine derivatives on p53 protein level
Pharmacological Reports (2020)
-
Awakening the “guardian of genome”: reactivation of mutant p53
Cancer Chemotherapy and Pharmacology (2019)
-
ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways
Oncogene (2018)
-
CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo
Tumor Biology (2016)